Clomifene Citrate
Brand names: Clomid, Serophene
Clomifene citrate is an oral selective oestrogen receptor modulator used to induce ovulation in anovulatory subfertility.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
By blocking hypothalamic oestrogen receptors it disrupts negative feedback, increasing gonadotrophin-releasing hormone and pituitary FSH and LH output to stimulate follicular development.
Prescribing in practice
- There is an increased risk of multiple pregnancy and of ovarian hyperstimulation syndrome, so use should be supervised with cycle monitoring.
- Treatment is given for a limited number of cycles and prolonged or repeated courses are not recommended because of concern about ovarian effects.
- Visual disturbances are a recognised effect and treatment should be stopped if they occur.
Monitoring
Monitor the ovarian response, ideally with ultrasound, to guide treatment and reduce the risk of multiple pregnancy and hyperstimulation.
Counselling the patient
- Be aware of an increased chance of twins or higher-order pregnancy.
- Stop the medicine and seek advice if you experience visual symptoms such as blurring or flashes.
- Report severe abdominal pain or bloating, which may indicate ovarian overstimulation.
Evidence & guidelines
Clomifene is a long-established first-line ovulation-induction agent; treatment should follow specialist fertility guidance and the SPC.
Reference: NICE NG156 (Fertility); RCOG OHSS Guideline 2016; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016